Biotech News
Nektar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
ir.nektar.com2026-05-06 15:29 EST
SAN FRANCISCO, March 12, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter ended December 31, 2025. Cash and investments in marketable securities on December 31, 2025 were $245.8 million as compared to $269.1 million on December 31,